BioSyent Inc. (RX.V)
- Previous Close
8.40 - Open
8.44 - Bid 8.34 x --
- Ask 8.46 x --
- Day's Range
8.40 - 8.61 - 52 Week Range
7.03 - 9.26 - Volume
65,245 - Avg. Volume
6,190 - Market Cap (intraday)
97.521M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
15.85 - EPS (TTM)
0.53 - Earnings Date May 24, 2024 - May 28, 2024
- Forward Dividend & Yield 0.18 (2.14%)
- Ex-Dividend Date Feb 28, 2024
- 1y Target Est
9.00
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.
www.biosyent.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: RX.V
Performance Overview: RX.V
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RX.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RX.V
Valuation Measures
Market Cap
97.52M
Enterprise Value
72.55M
Trailing P/E
15.82
Forward P/E
17.86
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.24
Price/Book (mrq)
2.81
Enterprise Value/Revenue
2.30
Enterprise Value/EBITDA
8.01
Financial Highlights
Profitability and Income Statement
Profit Margin
20.45%
Return on Assets (ttm)
11.39%
Return on Equity (ttm)
18.97%
Revenue (ttm)
31.59M
Net Income Avi to Common (ttm)
6.46M
Diluted EPS (ttm)
0.53
Balance Sheet and Cash Flow
Total Cash (mrq)
26.19M
Total Debt/Equity (mrq)
3.51%
Levered Free Cash Flow (ttm)
4.08M
Research Analysis: RX.V
Company Insights: RX.V
RX.V does not have Company Insights